-
欢迎监督和反馈:小木虫仅提供交流平台,不对该内容负责。
本内容由用户自主发布,如果其内容涉及到知识产权问题,其责任在于用户本人,如对版权有异议,请联系邮箱:libolin3@tal.com
- 附件 1 : 1._Current_Trends_for_Conducting_Clinical_Trials_in_Asia_Pacific_(PDF).pdf
2018-12-11 15:28:15, 28.71 M
- 附件 2 : 3-FangningZhangMcKinsey.pdf
2018-12-11 15:28:17, 10.06 M
- 附件 3 : 4-AlexForrest的When_Something_Goes_Wrong_in_a_Clinical_Trial-_Whoes_Liable_(PDF).pdf
2018-12-11 15:28:18, 522.57 K
- 附件 4 : 5__Case_Study_1__Rydapt_(Midostaurin)__Its_Odyssey_from_Discovery_to_Approval_for_Treating_(PDF).pdf
2018-12-11 15:28:19, 2.14 M
- 附件 5 : 6-Precision_Medicine___Challenges_&_Opportunities_for_the_Statistician_(PDF).pdf
2018-12-11 15:28:20, 4.77 M
- 附件 6 : 7-GloriaWang的A部分Cell_Therapy_Clinical_Development_What_Are_the_Critical_Factors_to_Consider_When_Conducting_Trials_in_China.pdf
2018-12-11 15:28:21, 610.53 K
- 附件 7 : 7-LiminWen的B部分__Cell_Therapy_Clinical_Development_What_Are_the_Critical_Factors_to_Consider_When_Conducting_Trials_in_China.pdf
2018-12-11 15:28:21, 1.1 M
- 附件 8 : 9-XiaoxiangChen的Elevated_Global_Clinical_Research_Driven_by_Chinese_Innovation___The_New_Normal_(PDF).pdf
2018-12-11 15:28:22, 4.81 M
- 附件 9 : 10-YeHua的Accelerated_Approval_Strategies___Which_Regulatory_Path_Should_You_Select_for_Your_New_Drug_Registration_(PDF).pdf
2018-12-11 15:28:23, 5.9 M
- 附件 10 : 11-SanjeevYong的Combination_Therapy_of_Novel_or_Novel_Compounds_(PDF).pdf
2018-12-11 15:28:26, 18.57 M
- 附件 11 : 12-HoweLi的part_B_Protecting_the_Rights,_Safety_and_Welfare_of_Study_Subjects_in_Clinical_Trials.pdf
2018-12-11 15:28:27, 1.14 M
- 附件 12 : 12-SeanZhao的part_A___Protecting_the_Rights,_Safety_and_Welfare_of_Study_Subjects_in_Clinical_Trials.pdf
2018-12-11 15:28:27, 929.52 K
- 附件 13 : 12-YanWu的part_C_Protecting_the_Rights,_Safety_and_Welfare_of_Study_Subjects_in_Clinical_Trials.pdf
2018-12-11 15:28:31, 28.76 M